US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ODDITY Tech Ltd.

70.07

+0.58000.83%

Post-market: 70.07-0.00010.00%17:19 EDT

Volume:749.47K

Turnover:52.60M

Market Cap:3.91B

PE:40.34

High:71.11

Open:70.14

Low:69.12

Close:69.49

Loading ...

Overview Company News Filings

Pharming Group reports second quarter and first half 2025 financial results and provides business update

ODDITY Tech Ltd. Class A (ODD) Gets a Buy from Truist Financial

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

ODDITY to Announce Second Quarter 2025 Financial Results on August 4, 2025

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Bank of America Securities Sticks to Its Buy Rating for ODDITY Tech Ltd. Class A (ODD)

ODDITY Tech Is Maintained at Equal-Weight by Barclays

Barclays Remains a Hold on ODDITY Tech Ltd. Class A (ODD)

ODDITY Tech Is Maintained at Overweight by Keybanc

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

ODDITY Tech Is Maintained at Buy by B of A Securities

Oddity price target raised to $80 from $68 at BofA

Buy Rating for ODDITY Tech Ltd.: Strong Market Position and Growth Potential in the Beauty Industry

ODDITY Tech Completes $600 Million Notes Offering with Capped Call Transactions

Oddity Tech Ltd. Files Prospectus for $600 Million Exchangeable Notes Offering Due 2030

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ODD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":70.07,"timestamp":1753992000000,"preClose":69.49,"halted":0,"volume":749473,"hourTrading":{"tag":"盘后","latestPrice":70.0699,"preClose":70.07,"latestTime":"17:19 EDT","volume":27861,"amount":1952220.2699999998,"timestamp":1753996796420},"delay":0,"floatShares":38704922,"shares":55828291,"eps":1.736982,"marketStatus":"Post-Mkt","change":0.58,"latestTime":"07-31 18:31:11 EDT","open":70.14,"high":71.11,"low":69.12,"amount":52602999.13545,"amplitude":0.028637,"askPrice":70.06,"askSize":14,"bidPrice":62.22,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.736982,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1754006400000},"marketStatusCode":4,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":69.49,"preHourTrading":{"tag":"盘前","latestPrice":70.74,"preClose":69.49,"latestTime":"08:00 EDT","volume":1,"amount":70.74,"timestamp":1753963201073},"postHourTrading":{"tag":"盘后","latestPrice":70.0699,"preClose":70.07,"latestTime":"17:19 EDT","volume":27861,"amount":1952220.2699999998,"timestamp":1753996796420},"volumeRatio":0.985754,"impliedVol":0.6836,"impliedVolPercentile":0.72},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":38704922,"roa":"14.35%","roe":"32.25%","lyrEps":1.769608,"volumeRatio":0.985754,"shares":55828291,"dividePrice":0,"high":71.11,"amplitude":0.028637,"preClose":69.49,"low":69.12,"week52Low":32.71,"pbRate":"11.86","psRate":"5.56","week52High":79.1804,"institutionHeld":0,"latestPrice":70.07,"committee":0.754386,"eps":1.736982,"divideRate":0,"volume":749473,"delay":0,"ttmEps":1.736982,"open":70.14,"prevYearClose":42.02,"prevWeekClose":67.89,"prevMonthClose":75.47,"prevQuarterClose":75.47,"fiveDayClose":69.43,"twentyDayClose":75.11,"sixtyDayClose":64.13,"earningDate":1754236800000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555008794","title":"Pharming Group reports second quarter and first half 2025 financial results and provides business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2555008794","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555008794?lang=en_us&edition=fundamental","pubTime":"2025-07-31 13:00","pubTimestamp":1753938000,"startTime":"0","endTime":"0","summary":"Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST and Joenja revenue growthRUCONEST second quarter revenue increase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124636/0/en/Pharming-Group-reports-second-quarter-and-first-half-2025-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","BK4215","BK4566","BK4585","EEA","ODD","BK4183","MAA","CHMP","BK4139","BK4588","IE00BFMHRM44.USD","NICE","EMA","BK4081","BK4087","BK4543","PHAR","BK4023","IE0009354923.USD"],"gpt_icon":0},{"id":"2555053921","title":"ODDITY Tech Ltd. Class A (ODD) Gets a Buy from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2555053921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555053921?lang=en_us&edition=fundamental","pubTime":"2025-07-29 19:18","pubTimestamp":1753787921,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Youssef Squali maintained a Buy rating on ODDITY Tech Ltd. Class A today. The company’s shares closed yesterday at $68.43....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oddity-tech-ltd-class-a-odd-gets-a-buy-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oddity-tech-ltd-class-a-odd-gets-a-buy-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2553788116","title":"Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology","url":"https://stock-news.laohu8.com/highlight/detail?id=2553788116","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553788116?lang=en_us&edition=fundamental","pubTime":"2025-07-24 20:00","pubTimestamp":1753358400,"startTime":"0","endTime":"0","summary":"OLC was well-tolerated and enabled serum phosphate control in over 90% of patients with a low pill burdenLOS ALTOS, Calif., July  24, 2025  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/24/3121018/0/en/Unicycive-Therapeutics-Announces-the-Publication-of-Oxylanthanum-Carbonate-Pivotal-Trial-Data-in-Clinical-Journal-of-the-American-Society-of-Nephrology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4183","ODD","BK4006","UNCY","BK4007","LU0170899867.USD","IE00BZ1G4Q59.USD","LU0882574139.USD","BK4117","IE0009354923.USD","AFG","LU0971096721.USD","LU0149725797.USD","CMC","IE00B1BXHZ80.USD","LU0267386448.USD","BK4539","IE00BHPRN162.USD","LU1363072403.SGD","BK4139","LENZ","BK4107"],"gpt_icon":0},{"id":"2553401102","title":"ODDITY to Announce Second Quarter 2025 Financial Results on August 4, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553401102","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553401102?lang=en_us&edition=fundamental","pubTime":"2025-07-24 04:05","pubTimestamp":1753301100,"startTime":"0","endTime":"0","summary":"NEW YORK, July  23, 2025  (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (“ODDITY”) (NASDAQ: ODD), today announced that it will release its second quarter 2025 financial results after the market close on Monday","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/23/3120617/0/en/ODDITY-to-Announce-Second-Quarter-2025-Financial-Results-on-August-4-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2552489974","title":"Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies","url":"https://stock-news.laohu8.com/highlight/detail?id=2552489974","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552489974?lang=en_us&edition=fundamental","pubTime":"2025-07-17 20:00","pubTimestamp":1752753600,"startTime":"0","endTime":"0","summary":"The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The E","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/17/3117145/0/en/Praxis-Precision-Medicines-Receives-FDA-Breakthrough-Therapy-Designation-for-Relutrigine-for-the-Treatment-of-Seizures-Associated-with-SCN2A-and-SCN8A-Developmental-and-Epileptic-E.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","BK4200","BK4135","ASO","BK4561","IE0009354923.USD","BK4139","BK4183","CNS","ODD","PRAX"],"gpt_icon":0},{"id":"2551478551","title":"Bank of America Securities Sticks to Its Buy Rating for ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551478551","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551478551?lang=en_us&edition=fundamental","pubTime":"2025-07-16 18:50","pubTimestamp":1752663033,"startTime":"0","endTime":"0","summary":"In a report released today, Anna Lizzul from Bank of America Securities maintained a Buy rating on ODDITY Tech Ltd. Class A, with a price target of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","BAC"],"gpt_icon":0},{"id":"2551551192","title":"ODDITY Tech Is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2551551192","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551551192?lang=en_us&edition=fundamental","pubTime":"2025-07-16 03:59","pubTimestamp":1752609540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 15, 2025 15:59 ET (19:59 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"gpt_icon":0},{"id":"2551159507","title":"Barclays Remains a Hold on ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551159507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551159507?lang=en_us&edition=fundamental","pubTime":"2025-07-15 14:26","pubTimestamp":1752560818,"startTime":"0","endTime":"0","summary":"Barclays analyst Lauren Lieberman maintained a Hold rating on ODDITY Tech Ltd. Class A today and set a price target of $73.00. The company’s shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-oddity-tech-ltd-class-a-odd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"gpt_icon":0},{"id":"2551518919","title":"ODDITY Tech Is Maintained at Overweight by Keybanc","url":"https://stock-news.laohu8.com/highlight/detail?id=2551518919","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551518919?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:45","pubTimestamp":1752497100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 14, 2025 08:45 ET (12:45 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2550597929","title":"Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2550597929","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550597929?lang=en_us&edition=fundamental","pubTime":"2025-07-11 21:36","pubTimestamp":1752240960,"startTime":"0","endTime":"0","summary":"– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amylo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/11/3114044/0/en/Immix-Biopharma-Announces-Class-Leading-Safety-Profile-Allowing-Potential-Future-Indication-Expansion.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183","KOL"],"gpt_icon":0},{"id":"2550766821","title":"Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2550766821","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550766821?lang=en_us&edition=fundamental","pubTime":"2025-07-10 04:01","pubTimestamp":1752091260,"startTime":"0","endTime":"0","summary":"Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and W","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/09/3112864/0/en/Nurix-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0347712357.USD","LU1066051498.USD","LU2229751404.USD","LU1712237335.SGD","LU1917777945.USD","IE00B19Z3581.USD","LU0058720904.USD","LU0689626769.HKD","NRIX","SGXZ57979304.SGD","LU0289960550.SGD","LU2092937221.SGD","WM","LU1023059063.AUD","LU2211814178.USD","LU1989772840.SGD","LU1923621640.USD","LU2362541513.USD","LU2240825500.USD","ORR","BK4599","SG9999002224.SGD","ODD","CNS","EMA","LU1892829315.USD","LU0321505439.SGD","IE0009354923.USD","IE00BLSP4452.SGD","LU2413666426.HKD","LU2298064838.USD","LU1066053197.SGD","LU0456855351.SGD","LU2041044095.USD","LU2023250504.SGD","BK4566","LU0289961442.SGD","LU2023250843.SGD","SG9999013999.USD","CR","BK4585","LU0175139822.USD","BK4581","LU2355687059.USD","BK4588","IE00B19Z3B42.SGD","LU0306807586.USD","LU1894683348.USD"],"gpt_icon":1},{"id":"2549225542","title":"Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2549225542","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549225542?lang=en_us&edition=fundamental","pubTime":"2025-07-08 20:30","pubTimestamp":1751977800,"startTime":"0","endTime":"0","summary":"--Nasdaq compliance follows reverse stock split previously announced on June 17, 2025LOS ALTOS, Calif., July  08, 2025  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(“Unicycive” or the “Company”) (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111744/0/en/Unicycive-Therapeutics-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","TSYW.SI","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","USAW.SI","IE0009354923.USD","LU2210149790.SGD","QLD","TQQQ","IE00BKPKM429.USD","QID","BK4539","NVIW.SI","BK4183","PSQ","IE00B64PRP62.GBP",".IXIC","BK4007","ODD","UNCY","MNQmain","NDAQ","NQmain","BK4139","USJW.SI","IE00B3QW5Z07.USD","SQQQ","LU2095319765.USD","BK4588","LENZ"],"gpt_icon":1},{"id":"2549530799","title":"Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2549530799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549530799?lang=en_us&edition=fundamental","pubTime":"2025-07-07 21:35","pubTimestamp":1751895300,"startTime":"0","endTime":"0","summary":"– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication –  – NEXICART-2 interim result","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3111088/0/en/Immix-Biopharma-Announces-Accelerated-NEXICART-2-Clinical-Trial-Progress-in-relapsed-refractory-AL-Amyloidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","IE0009354923.USD","LU2065732104.USD","IE00B19Z6F94.USD","AL","BK4097","BK4572","LU1169589451.USD","ODD","BK4104","BK4183","LU1169590202.USD","IE0034390439.USD","KOL"],"gpt_icon":0},{"id":"2549539298","title":"European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2549539298","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549539298?lang=en_us&edition=fundamental","pubTime":"2025-07-07 19:00","pubTimestamp":1751886000,"startTime":"0","endTime":"0","summary":"Regulatory momentum builds for bexobrutideg with multiple designations across the United States and EU, Including EMA PRIME and FDA Fast Track for CLL/SLLSAN FRANCISCO, July  07, 2025  (GLOBE NEWSWIRE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3110913/0/en/European-Medicines-Agency-Grants-Bexobrutideg-NX-5948-Orphan-Drug-Designation-for-the-Treatment-of-Lymphoplasmacytic-Lymphoma-also-Known-as-Waldenstr%C3%B6m-Macroglobulinemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","LU1623119135.USD","LU2238339852.HKD","LU2065732104.USD","LU2089279066.USD","LU2413666699.HKD","ODD","BK4533","LU1939255532.USD","LU1989772923.USD","LU0057025933.USD","LU2362541273.HKD","LU0472753341.HKD","LU2125910336.SGD","LU0124676726.USD","LU0175139822.USD","BK4585","IE0009354923.USD","LU0289961442.SGD","LU1585245621.USD","BK4534","LU2023250843.SGD","LU2041044095.USD","BK4086","LU2092937221.SGD","EMA","LU1721428933.USD","LU2240825500.USD","LU0511384066.AUD","LU2298064838.USD","LU0689626769.HKD","LU1892829315.USD","LU2106854487.HKD","LU0347712357.USD","BK4566","LU1712237335.SGD","LU1917777945.USD","LU2413666426.HKD","LU1974910355.USD","LU2211814178.USD","MDCO","NX","BK4081","WM","LU2229751404.USD","LU1430594728.SGD","LU2023250504.SGD","BK4183","BK4120","LU0289960550.SGD"],"gpt_icon":0},{"id":"2549539217","title":"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2549539217","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549539217?lang=en_us&edition=fundamental","pubTime":"2025-07-07 19:00","pubTimestamp":1751886000,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., July  07, 2025  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3110898/0/en/Unicycive-Therapeutics-to-Present-at-the-H-C-Wainwright-4th-Annual-Kidney-Virtual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","UNCY","BK4007","ODD","BK4539","BK4139","BK4183","IE0009354923.USD"],"gpt_icon":0},{"id":"2546426567","title":"ODDITY Tech Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2546426567","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546426567?lang=en_us&edition=fundamental","pubTime":"2025-06-27 22:35","pubTimestamp":1751034900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 27, 2025 10:35 ET (14:35 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2546710605","title":"Oddity price target raised to $80 from $68 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2546710605","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546710605?lang=en_us&edition=fundamental","pubTime":"2025-06-27 18:50","pubTimestamp":1751021430,"startTime":"0","endTime":"0","summary":"BofA analyst Anna Lizzul raised the firm’s price target on Oddity (ODD) to $80 from $68 and keeps a Buy rating on the shares as the firm transfered...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oddity-price-target-raised-to-80-from-68-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oddity-price-target-raised-to-80-from-68-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","BK4183","IE0009354923.USD"],"gpt_icon":0},{"id":"2546717199","title":"Buy Rating for ODDITY Tech Ltd.: Strong Market Position and Growth Potential in the Beauty Industry","url":"https://stock-news.laohu8.com/highlight/detail?id=2546717199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546717199?lang=en_us&edition=fundamental","pubTime":"2025-06-27 18:37","pubTimestamp":1751020666,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A (ODD – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Anna Lizzul ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-oddity-tech-ltd-strong-market-position-and-growth-potential-in-the-beauty-industry-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-oddity-tech-ltd-strong-market-position-and-growth-potential-in-the-beauty-industry-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2543653941","title":"ODDITY Tech Completes $600 Million Notes Offering with Capped Call Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2543653941","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543653941?lang=en_us&edition=fundamental","pubTime":"2025-06-14 05:51","pubTimestamp":1749851499,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A ( ($ODD) ) has shared an update. On June 12, 2025, Oddity Finance LLC, a subsidiary of ODDITY Tech Ltd., completed a priva...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-completes-600-million-notes-offering-with-capped-call-transactions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-completes-600-million-notes-offering-with-capped-call-transactions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","IE0009354923.USD","ODD"],"gpt_icon":0},{"id":"2543127658","title":"Oddity Tech Ltd. Files Prospectus for $600 Million Exchangeable Notes Offering Due 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2543127658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543127658?lang=en_us&edition=fundamental","pubTime":"2025-06-14 05:19","pubTimestamp":1749849589,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd. has filed a prospectus for a private offering of $600 million in 0% Exchangeable Senior Notes due in 2030. The offering was completed by its subsidiary, Oddity Finance LLC, and includes a full exercise of the initial purchasers' option to buy an additional $75 million in notes. The notes are fully guaranteed by ODDITY Tech and its subsidiary IM Pro Makeup NY L.P. An indenture agreement was signed on June 12, 2025, involving ODDITY Tech, IM Pro, and U.S. Bank Trust Company. The notes will be exchangeable at a rate tied to ODDITY Tech's Class A ordinary shares, with a premium over the recent NASDAQ share price. Additionally, capped call transactions were entered to mitigate potential dilution of shares upon exchange of the notes, set at a cap premium of 100% over the last sale price on June 9, 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDLbWnTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4559","LU0170899867.USD","BK4585","BK4504","IE0009354923.USD","LU2237438978.USD","BK4207","BK4588","IE00BFXG1179.USD","USB","ODD"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":134,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"date":"2025-08-04","symbol":"ODD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.79,"defaultRemindTime":1754337600000,"name":null,"time":"Post Market","dateTimestamp":1754280000000,"actualEps":null},{"market":"US","date":"2025-04-29","symbol":"ODD","fiscalQuarterEnding":"2025/03","expectedEps":0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"post","actualEps":0.63},{"market":"US","date":"2025-02-25","symbol":"ODD","fiscalQuarterEnding":"2024/12","expectedEps":0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"post","actualEps":0.06},{"market":"US","date":"2024-11-06","symbol":"ODD","fiscalQuarterEnding":"2024/09","expectedEps":0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":0.29},{"market":"US","date":"2024-08-07","symbol":"ODD","fiscalQuarterEnding":"2024/06","expectedEps":0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":0.71}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.5556,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1738382400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2025-07-30","current":36.587457,"percent":0.658635,"low":20.831575,"twenty":24.975469,"median":31.640473,"eighty":41.865414,"high":144.174884,"avg":35.111557,"sd":16.788563,"marketCap":3890673599},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-13","current":38.84497,"twenty":24.888137,"median":31.181916,"eighty":42.353632,"marketCap":4130735251},{"date":"2025-06-20","current":36.618957,"twenty":24.907308,"median":31.267028,"eighty":42.321149,"marketCap":3894023297},{"date":"2025-06-27","current":37.637463,"twenty":24.9212,"median":31.363758,"eighty":42.207431,"marketCap":4002330181},{"date":"2025-07-03","current":39.798375,"twenty":24.940682,"median":31.434913,"eighty":42.187798,"marketCap":4232119427},{"date":"2025-07-11","current":38.424967,"twenty":24.946182,"median":31.476041,"eighty":42.12028,"marketCap":4086072618},{"date":"2025-07-18","current":37.17546,"twenty":24.957184,"median":31.58513,"eighty":42.056896,"marketCap":3953201285},{"date":"2025-07-25","current":36.450956,"twenty":24.962685,"median":31.617964,"eighty":41.958776,"marketCap":3876158244},{"date":"2025-07-30","current":36.587457,"twenty":24.975469,"median":31.640473,"eighty":41.865414,"marketCap":3890673599}],"updateTime":1753961430531}}}